Datasets:
hugging-science
/
jain-developability-clean

Dataset card Data Studio Files
xet
Community
1
name
stringlengths
8
13
light_chain_class
stringclasses
2 values
type
stringclasses
5 values
original_mab_isotype_or_format
stringclasses
17 values
clinical_status
stringclasses
3 values
phagec
bool
2 classes
year_name_proposed
int64
1.99k
2.01k
metadata_notes
stringclasses
3 values
vh
stringlengths
112
130
vl
stringlengths
104
113
lc_class
stringclasses
2 values
source
stringclasses
3 values
source_detaileda
stringlengths
4
9
disclaimers_and_known_issues
stringclasses
6 values
sequence_info_notes
stringclasses
1 value
hek_titer_mg_l
float64
6.58
277
fab_tm_by_dsf_deg_c
float64
59.5
91.5
sgac_sins_as100_nh4_2so4_mm
float64
0
1k
hic_retention_time_min_a
float64
8.47
25
smac_retention_time_min_a
float64
8.49
25
slope_for_accelerated_stability
float64
-0.01
1.27
poly_specificity_reagent_psr_smp_score_0_1
float64
0
0.81
affinity_capture_self_interaction_nanoparticle_spectroscopy_ac_sins_delta_lambda_max_nm_average
float64
-1.08
29.9
cic_retention_time_min
float64
8.26
13.5
csi_bli_delta_response_nm
float64
-0.05
0.6
elisa
float64
0.89
14.5
bvp_elisa
float64
1.03
22.7
abituzumab
kappa
ZU
IgG2
Phase 2
false
2,013
a Made with human isotype
QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK
kappa
WHO-INN
PL109
null
aPL and RL refer to WHO-INN publications for proposed and recommended lists
89.555458
75.5
900
9.227
8.725
0.05563
0.166666
1.458861
8.621
0
1.137375
2.720799
abrilumab
kappa
HU
IgG2
Phase 2
false
2,014
b Mixed chimeric, humanized LC and HC
QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK
kappa
WHO-INN
PL111
null
null
100.223196
71
900
9.413
8.699
0.02829
0
-0.928526
8.384
-0.02
1.124624
1.818303
adalimumab
kappa
HU
IgG1
Approved
true
1,999
c Most as those molecules labeled Yes in the phage column were discovered and or optimized by phage display. A small number of these were optimized by fragment-based phage techniques not involving display.
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK
kappa
PDB
4NYL
null
null
134.928638
71
900
8.816
8.672
0.05069
0
1.062328
8.865
-0.01
1.075515
1.488186
alemtuzumab
kappa
ZU
IgG1
Approved
false
2,000
null
QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK
kappa
PDB
1BEY
null
null
144.653543
74.5
1,000
8.769
8.672
0.06431
0
-0.789199
8.514
-0.02
1.161491
1.464226
alirocumab
kappa
HU
IgG1
Approved
false
2,012
null
EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS
DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK
kappa
WHO-INN
PL107
null
null
69.232345
71.5
900
9.036
8.681
0.0292
0
1.230511
8.757
-0.01
1.196224
2.1797
anifrolumab
kappa
HU
IgG1
Phase 3
false
2,013
null
EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK
kappa
WHO-INN
PL109
null
null
82.046821
62.5
700
8.799
8.629
0.0708
0
-0.561397
8.489
-0.02
1.15745
1.623295
atezolizumab
kappa
ZU
IgG1-no-glyco
Approved
true
2,014
null
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK
kappa
WHO-INN
PL112
null
null
164.085804
73.5
300
13.353
19.283
0.0556
0.065812
14.971122
10.76
0.06
1.294746
6.197378
bapineuzumab
kappa
ZU
IgG1
Phase 3
false
2,005
null
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS
DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK
kappa
US Patent
US7582733
Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL
null
151.09165
73
1,000
8.855
8.655
0.07017
0
-0.734256
8.619
0.06
1.20895
3.548752
basiliximab
kappa
XI
IgG1
Approved
false
1,996
null
QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS
QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK
kappa
PDB
1MIM
null
null
107.461588
60.5
0
9.578
8.576
0.0476
0.397164
28.757059
9.449
0
1.201328
2.138577
bavituximab
kappa
XI
IgG1
Phase 3
false
2,006
null
EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS
DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK
kappa
WHO-INN
PL95
null
null
45.110274
59.5
0
11.499
12.689
0.0404
0.557037
29.851202
11.395
-0.01
1.315456
1.692884
belimumab
lambda
HU
IgG1
Approved
true
2,003
null
QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS
SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL
lambda
US Patent
US8101181
null
null
10.472727
60
800
10.461
9.267
0.1304
0
0.771252
8.588
-0.03
3.609535
12.228952
benralizumab
kappa
ZU
IgG1
Phase 3
false
2,009
null
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK
kappa
WHO-INN
PL102
null
null
146.712684
76
800
9.467
9.09
0.0243
0.353712
5.977933
9.628
-0.01
1.231263
1.424719
bevacizumab
kappa
ZU
IgG1
Approved
false
2,000
null
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
kappa
PDB
1BJ1
null
null
49.978578
63.5
700
11.772
11.07
0.2198
0
0.79022
9.822
-0.02
1.285914
2.784692
bimagrumab
lambda
HU
IgG1
Phase 3
true
2,012
null
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL
lambda
WHO-INN
PL108
null
null
150.238851
72
0
10.125
8.829
0.09126
0.696556
29.645095
12.328
0.1
1.548608
5.327787
blosozumab
kappa
ZU
IgG4-CPPC
Phase 2
true
2,011
null
QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK
kappa
WHO-INN
PL105
null
null
120.009752
70.5
600
9.241
8.626
0.1252
0.208243
11.472476
8.866
0.46
13.177765
12.84792
bococizumab
kappa
ZU
IgG2
Phase 3
true
2,013
null
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK
kappa
WHO-INN
PL110
null
null
95.786921
67
0
10.179
9.108
0.067
0.760184
29.645095
10.595
0.5
13.496458
18.877205
brentuximab
kappa
XI
IgG1-ADC
Approved
false
2,010
null
QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA
DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK
kappa
WHO-INN
PL103
null
null
268.061982
72
800
10.535
8.683
-0.003086
0.247488
-0.542427
8.551
-0.03
4.2116
2.242928
briakinumab
lambda
HU
IgG1
Phase 3
true
2,009
null
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS
QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL
lambda
WHO-INN
PL101
null
null
121.992234
71.5
0
9.359
8.737
0.1054
0.556059
29.645095
10.394
0.02
4.829996
10.217637
brodalumab
kappa
HU
IgG2
Phase 3
false
2,011
null
QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK
kappa
WHO-INN
PL105
null
null
150.862586
74.5
900
9.079
8.743
0.01717
0.26549
11.207609
8.971
-0.01
1.475125
2.92579
canakinumab
kappa
HU
IgG1
Approved
false
2,007
null
QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS
EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK
kappa
US Patent
US8105587
null
null
45.724929
72
800
9.321
8.727
0.03791
0
0.669938
8.635
0
1.195418
2.545757
carlumab
kappa
HU
IgG1
Phase 2
true
2,010
null
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK
kappa
WHO-INN
PL104
null
null
243.323478
69.5
700
11.167
9.31
0.07491
0.211582
-0.438032
8.62
-0.02
2.761083
8.879201
certolizumab
kappa
ZU
FabPEG
Approved
false
2,004
null
EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK
kappa
US Patent
US7402662
null
null
186.709369
81.5
500
11.478
10.815
0.04289
0
0.163095
9.314
-0.01
1.143818
1.64792
cetuximab
kappa
XI
IgG1
Approved
false
1,999
null
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK
kappa
PDB
1YY8
null
null
109.160445
68.5
400
10.11
8.91
0.05474
0
1.299961
8.906
-0.04
1.09328
1.085524
cixutumumab
lambda
HU
IgG1
Phase 2
true
2,008
null
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS
SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL
lambda
WHO-INN
PL100
null
null
154.25963
73.5
0
11.76
10.723
0.1617
0.657024
29.645095
9.664
0.38
3.766344
11.90416
clazakizumab
kappa
ZU
IgG1
Phase 2
false
2,012
null
EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS
AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK
kappa
WHO-INN
PL107
null
null
113.477347
69.5
800
9.568
8.871
0.05306
0
0.930046
8.729
-0.03
1.281554
4.115141
codrituzumab
kappa
ZU
IgG1
Phase 2
false
2,013
null
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS
DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK
kappa
WHO-INN
PL109
null
null
66.347408
73
1,000
8.836
8.592
0.255
0.147987
-0.285719
8.454
-0.01
9.418865
14.874542
crenezumab
kappa
ZU
IgG4-CPPC
Phase 3
false
2,011
null
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS
DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
kappa
WHO-INN
PL105
null
null
149.265977
72
700
10.031
8.703
0.04786
0.104936
6.3708
8.899
0
1.133396
2.780699
dacetuzumab
kappa
ZU
IgG1
Phase 2
false
2,007
null
EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK
kappa
WHO-INN
PL98
null
null
128.452216
68
1,000
8.466
8.614
0.0033
0
-0.014676
8.467
-0.04
1.079326
1.335206
daclizumab
kappa
ZU
IgG1
Approved
false
1,994
null
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS
DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK
kappa
PDB
3NFP
null
null
245.107923
74
900
9.286
8.751
0.02794
0
-0.110586
8.476
-0.02
1.180366
1.414309
dalotuzumab
kappa
ZU
IgG1
Phase 2
false
2,009
null
QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS
DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK
kappa
US Patent
US7914784
Entries in WHO-INN documents (PL102 and RL64) have errors
null
82.41734
77
800
9.891
8.704
0.1466
0.399648
13.68059
9.118
0.14
2.898655
8.253577
daratumumab
kappa
HU
IgG1
Approved
false
2,009
null
EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK
kappa
WHO-INN
PL101
null
null
233.334298
71
800
9.514
8.926
0.06363
0
1.80923
8.855
0
1.213584
3.151414
denosumab
kappa
HU
IgG2
Approved
false
2,005
null
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK
kappa
US Patent
US7364736
null
null
134.167846
69.5
1,000
8.501
8.603
0.01043
0
5.907925
8.811
0.11
5.917966
17.74975
dinutuximab
kappa
XI
IgG1
Approved
false
2,013
null
EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS
EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
kappa
WHO-INN
PL109
null
null
76.42882
69
800
9.833
8.963
0.0098
0.302741
3.635206
9.405
-0.02
1.030887
1.69176
drozitumab
lambda
HU
IgG1
Phase 2
true
2,010
null
EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS
SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL
lambda
WHO-INN
PL103
null
null
22.068896
63
0
9.29
8.716
0.02829
0
29.645095
8.79
0.04
1.096797
1.479534
duligotuzumab
kappa
ZU
IgG1
Phase 2
true
2,012
null
EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK
kappa
WHO-INN
PL107
null
null
192.582804
67.5
0
10.206
8.938
0.05514
0.33444
29.645095
9.53
0.6
8.539748
9.630616
dupilumab
kappa
HU
IgG4-CPPC
Phase 3
false
2,012
null
EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS
DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK
kappa
WHO-INN
PL108
null
null
163.549147
76.5
700
10.159
9.009
0.02874
0.146876
10.804212
9.752
-0.01
8.694358
19.270549
eculizumab
kappa
ZU
IgG24
Approved
false
2,002
null
QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK
kappa
US Patent
US6355245
null
null
226.468532
66
700
10.41
9.277
0.008
0
0.043333
8.499
-0.04
0.959428
2.995506
efalizumab
kappa
ZU
IgG1
Approved
false
2,001
null
EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK
kappa
PDB
3EOA
null
null
166.992344
72.5
900
8.668
8.641
0
0
0.681276
8.542
-0.02
0.98291
1.238202
eldelumab
kappa
HU
IgG1
Phase 2
false
2,013
null
QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK
kappa
WHO-INN
PL109
null
null
89.253053
59.5
500
12.422
25
0.0998
0
1.21252
10.156
-0.02
1.109093
1.747088
elotuzumab
kappa
ZU
IgG1
Approved
false
2,008
null
EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK
kappa
WHO-INN
PL100
null
null
213.1906
83.5
700
10.314
9.288
0
0
-0.224469
8.469
-0.03
0.978042
1.264794
emibetuzumab
kappa
ZU
IgG4-CPPC
Phase 2
true
2,014
null
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK
kappa
WHO-INN
PL111
null
null
98.748918
71.5
0
9.638
8.684
0.04114
0.643143
29.645095
9.528
0.06
3.300083
8.329451
enokizumab
kappa
ZU
IgG1
Phase 2
true
2,010
null
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK
kappa
WHO-INN
PL104
null
null
239.819013
68
600
12.934
10.881
0.08966
0.125828
1.533553
9.028
-0.02
1.173417
3.239268
epratuzumab
kappa
ZU
IgG1
Phase 3
false
1,999
null
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS
DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK
kappa
US Patent
US5789554
null
null
78.230572
65
900
9.189
8.629
0.02629
0.130915
3.014187
8.689
-0.01
1.474552
2.342762
etrolizumab
kappa
ZU
IgG1
Phase 2
true
2,010
null
EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK
kappa
WHO-INN
PL104
null
null
173.842456
76
900
9.322
8.77
0.2009
0.420378
2.017646
8.768
-0.03
2.182071
4.228952
evolocumab
lambda
HU
IgG2
Approved
false
2,012
null
EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS
ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL
lambda
WHO-INN
PL108
null
null
260.677128
65
700
10.355
9.13
0.0298
0.204333
2.236431
9.254
-0.01
1.754453
1.754409
farletuzumab
kappa
ZU
IgG1
Phase 3
false
2,008
null
EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS
DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK
kappa
WHO-INN
PL100
null
null
220.817624
75.5
800
9.491
9.065
0.006029
0
-0.501925
8.687
-0.01
1.073797
1.321797
fasinumab
kappa
HU
IgG4-CPPC
Phase 3
false
2,012
null
QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS
DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK
kappa
WHO-INN
PL107
null
null
110.374487
71
900
10.026
8.715
0.06657
0
-0.671927
8.359
-0.02
1.156861
2.527121
fezakinumab
lambda
HU
IgG1
Phase 2
true
2,009
null
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS
QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL
lambda
WHO-INN
PL101
null
null
141.453494
69
600
11.798
13.709
0.06932
0.264712
2.50184
11.26
-0.0158
1.145613
2.146423
ficlatuzumab
kappa
ZU
IgG1
Phase 2
false
2,011
null
QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS
DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK
kappa
WHO-INN
PL105
null
null
249.025765
75
900
9.421
8.882
0.04614
0
-0.893786
8.488
-0.02
1.133884
1.233278
figitumumab
kappa
HU
IgG2
Phase 3
false
2,008
null
EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS
DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK
kappa
WHO-INN
PL100
null
null
119.916768
66.5
0
10.745
9.86
0.06446
0.378958
29.645095
10.533
0.02
2.893762
5.650582
fletikumab
kappa
HU
IgG4-CPPC
Phase 2
false
2,013
null
QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
kappa
WHO-INN
PL110
null
null
220.376225
71.5
700
11.038
9.143
0.01897
0
-0.125458
8.474
-0.02
1.024451
1.408319
foralumab
kappa
HU
IgG1
Phase 2
false
2,010
null
QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK
kappa
WHO-INN
PL103
null
null
174.435088
66
0
9.842
8.574
0.03766
0.371715
28.085284
9.324
0
4.767634
4.711481
fresolimumab
kappa
HU
IgG4
Phase 2
true
2,009
null
QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS
ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK
kappa
WHO-INN
PL101
null
null
166.036557
74
700
10.875
9.145
0.05526
0
-0.515083
8.466
-0.02
1.300181
3.512812
fulranumab
kappa
HU
IgG2
Phase 3
false
2,010
null
EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
kappa
WHO-INN
PL104
null
null
142.018924
68.5
900
9.328
9.342
0.07229
0.187679
11.560721
9.346
0
1.849308
6.923128
galiximab
lambda
XI
IgG1
Phase 2
false
2,003
null
QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS
ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL
lambda
US Patent
US6113898
null
null
174.116872
67.5
600
12.198
14.77
0.03135
0
1.093714
8.87
-0.02
1.213663
3.810316
ganitumab
kappa
HU
IgG1
Phase 3
true
2,010
null
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS
DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK
kappa
WHO-INN
PL103
null
null
229.43987
78.5
800
9.334
8.77
0.01174
0.552845
4.774833
9.482
-0.01
1.295156
4.907155
gantenerumab
kappa
HU
IgG1
Phase 3
true
2,007
null
QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS
DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK
kappa
WHO-INN
PL97
null
null
162.659011
77.5
1,000
9.004
8.487
0.06671
0.5526
6.957989
8.709
0.1
13.82019
22.74609
gemtuzumab
kappa
ZU
IgG4-ADC
Approved
false
2,000
null
EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS
DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK
kappa
US Patent
US5773001
null
null
171.299785
72.5
500
12.259
13.931
0.04534
0
1.020051
9.106
-0.01
1.080084
1.697837
gevokizumab
kappa
ZU
IgG2
Phase 3
false
2,010
null
QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS
DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK
kappa
WHO-INN
PL104
null
null
136.360641
71.5
1,000
8.828
8.607
0.07129
0
-0.51477
8.579
-0.03
1.18008
1.931448
girentuximab
kappa
XI
IgG1
Phase 3
false
2,009
null
DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS
DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK
kappa
WHO-INN
PL101
null
null
30.72183
63
1,000
9.081
8.683
0.03154
0
-0.751821
8.524
-0.04
1.090143
1.393677
glembatumumab
kappa
HU
IgG2
Phase 2
false
2,009
null
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS
EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK
kappa
WHO-INN
PL102
null
null
152.712345
70.5
0
13.68
25
0.303
0.166107
28.880635
13.5
0.01
1.063291
2.215356
golimumab
kappa
HU
IgG1
Approved
false
2,004
null
QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK
kappa
US Patent
US7250165
null
null
163.238323
70
0
11.359
12.747
0.06274
0.234008
22.965397
11.23
-0.01
1.309296
2.712146
guselkumab
lambda
HU
IgG1
Phase 3
true
2,013
null
EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS
QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL
lambda
WHO-INN
PL109
null
null
167.340129
69.5
700
11.403
9.195
0.1931
0.469339
3.367196
10.109
0.02
1.541176
5.867554
ibalizumab
kappa
ZU
IgG4
Phase 3
false
2,007
null
QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS
DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK
kappa
WHO-INN
PL97
null
null
133.282633
72
800
10.237
9.771
0.0393
0
-0.339304
8.66
-0.03
0.993142
1.126217
imgatuzumab
kappa
ZU
IgG1
Phase 2
false
2,012
null
QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK
kappa
WHO-INN
PL107
null
null
187.708497
71.5
800
10.09
8.898
0.06543
0
0.893874
8.994
-0.01
5.014941
11.774376
infliximab
kappa
XI
IgG1
Approved
false
1,997
null
EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS
DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK
kappa
PDB
4G3Y
null
null
6.581146
64.5
0
10.36
8.888
0.1812
0
29.645095
9.011
0.05
1.036832
1.371714
inotuzumab
kappa
ZU
IgG4-ADC
Phase 3
false
2,004
null
EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS
DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK
kappa
US Patent
US7355011
null
null
169.767062
83
800
9.717
9.052
0.02517
0.250008
4.029671
9.295
0.01
3.180205
5.395674
ipilimumab
kappa
HU
IgG1
Approved
false
2,005
null
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK
kappa
US Patent
US6984720
null
null
169.561868
73
400
11.57
12.981
0.03963
0.229631
10.413099
10.941
0.01
1.052425
1.691847
ixekizumab
kappa
ZU
IgG4-CPPC
Approved
true
2,011
null
QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS
DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK
kappa
WHO-INN
PL105
null
null
97.277433
83
500
10.936
9.082
0.1614
0.809817
19.952343
9.636
0.11
8.79746
10.398669
lampalizumab
kappa
ZU
Fab
Phase 3
false
2,012
null
EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS
DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK
kappa
WHO-INN
PL107
null
null
187.075402
67
800
9.25
8.765
0.08749
0
0.494177
8.455
-0.03
1.108848
1.340433
lebrikizumab
kappa
ZU
IgG4-CPPC
Phase 3
false
2,009
null
QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK
kappa
WHO-INN
PL101
null
null
61.607125
66
500
12.381
15.71
0.0047
0
0.255326
9.071
-0.04
0.962254
1.45618
lenzilumab
kappa
HU
IgG1
Phase 2
true
2,014
null
QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK
kappa
WHO-INN
PL111
null
null
184.742758
74
0
8.722
8.605
0.03277
0.655128
29.645095
10.122
0.02
14.459031
19.604659
lintuzumab
kappa
ZU
IgG1
Phase 3
false
1,996
null
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK
kappa
US Patent
US5530101
null
null
229.970848
75.5
700
10.874
9.428
0.048
0
0.885988
8.933
-0.02
1.045706
1.254576
lirilumab
kappa
HU
IgG4-CPPC
Phase 2
false
2,012
null
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS
EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK
kappa
WHO-INN
PL107
null
null
270.480297
70
300
25
25
0.00174
0.182914
20.998948
10.562
0.04
1.269556
3.549418
lumiliximab
kappa
XI
IgG1
Phase 2
false
2,004
null
EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK
kappa
US Patent
US6893636
null
null
86.273039
64.5
800
9.545
8.782
0.06686
0.144897
1.443549
8.815
-0.02
1.137911
2.218303
matuzumab
kappa
ZU
IgG1
Phase 2
false
2,003
null
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK
kappa
PDB
3C08
null
null
224.328821
72
900
9.84
8.834
0.0164
0
-0.927208
8.635
-0.03
1.059855
1.027621
mavrilimumab
lambda
HU
IgG4
Phase 2
true
2,009
null
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS
QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL
lambda
WHO-INN
PL102
null
null
150.548853
68.5
700
10.296
8.671
0.04903
0
-0.778754
8.496
-0.01
1.213082
2.16173
mepolizumab
kappa
ZU
IgG1AA-mut
Approved
false
1,999
null
QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK
kappa
US Patent
US5693323
null
null
221.475177
78.5
900
9.238
8.816
0.04451
0
-0.956637
8.408
-0.04
1.131191
1.051581
mogamulizumab
kappa
ZU
IgG1-glyco
Approved
false
2,010
null
EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS
DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK
kappa
WHO-INN
PL104
null
null
89.767929
68.5
800
9.641
8.82
0.03631
0
-0.511762
8.631
-0.02
1.118282
2.165724
motavizumab
kappa
ZU
IgG1
Phase 3
true
2,006
null
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS
DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK
kappa
PDB
3IXT
null
null
133.551595
86
800
9.689
8.82
0.04454
0
2.522763
8.66
-0.01
1.22954
5.360399
muromonab
kappa
XIa
IgG2a
Approved
false
1,988
null
QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIK
kappa
PDB
1SY6
Last residue of LC variable region changed from N to K. N would create a NRT N-glycosylation site when joined to human CK sequence
null
113.52288
74.5
1,000
8.899
8.578
0.03829
0.175892
2.311513
9.048
0.01
1.408897
3.937438
natalizumab
kappa
ZU
IgG4
Approved
false
1,998
null
QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK
kappa
US Patent
US5840299
null
null
251.745705
79.5
900
9.7
8.843
0.01877
0
0.822884
8.764
-0.01
1.063994
1.524792
necitumumab
kappa
HU
IgG1
Approved
true
2,008
null
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS
EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK
kappa
WHO-INN
PL100
null
null
198.599891
76.5
600
10.807
9.9
0.0204
0
1.300578
8.771
-0.02
1.045456
1.310483
nimotuzumab
kappa
ZU
IgG1
Approved
false
2,005
null
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT
kappa
PDB
3GKW
null
null
15.13165
65.5
900
25
8.884
0.04357
0
-0.585505
8.464
-0.02
1.318679
3.424293
nivolumab
kappa
HU
IgG4-CPPC
Approved
false
2,012
null
QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK
kappa
WHO-INN
PL107
null
null
178.809229
66
900
9.023
8.655
0.02743
0.135175
2.41804
8.853
-0.01
1.153877
1.324459
obinutuzumab
kappa
ZU
IgG1-glyco
Approved
false
2,009
null
QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
kappa
WHO-INN
RL65
null
null
176.441448
73
600
10.641
8.964
0.0128
0.112785
1.831573
8.8
-0.01
0.950558
1.629588
ocrelizumab
kappa
ZU
IgG1
Phase 3
false
2,005
null
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK
kappa
US Patent
US8562992
null
null
137.774414
70.5
300
9.911
8.83
0.0237
0
17.881994
9.532
0.01
1.128492
1.672659
ofatumumab
kappa
HU
IgG1
Approved
false
2,005
null
EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK
kappa
PDB
3GIZ
null
null
249.752167
68
800
9.729
9.524
0.02874
0
1.209699
9.248
-0.02
1.122143
1.176705
olaratumab
kappa
HU
IgG1
Phase 2
false
2,010
null
QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK
kappa
WHO-INN
PL103
null
null
141.936048
62.5
700
10.609
8.957
0.2885
0.483143
0.310395
9.417
-0.02
1.316067
2.584359
olokizumab
kappa
ZU
IgG4-CPPC
Phase 2
false
2,010
null
EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK
kappa
WHO-INN
PL103
null
null
115.258271
69
700
9.908
8.973
0.04469
0
-0.502615
8.749
-0.03
1.105369
1.229285
omalizumab
kappa
ZU
IgG1
Approved
false
2,000
null
EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSLKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK
kappa
PDB
2XA8
CDR-H2 has V to L mutation (unintended)
null
150.447109
77.5
800
9.519
8.744
0.04511
0
-0.438278
8.538
-0.02
1.116105
1.166057
onartuzumab
kappa
ZU
IgG1-One-armed
Phase 3
false
2,010
null
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK
kappa
WHO-INN
PL104
null
null
147.933138
80
800
9.919
8.869
0.04311
0
-0.046662
8.911
-0.02
1.119281
1.186689
otelixizumab
lambda
XIZUb
IgG1-no-glyco
Phase 3
false
2,007
null
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS
DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL
lambda
WHO-INN
PL98
null
null
152.082453
75.5
1,000
9.082
8.72
0.08814
0
4.438287
8.719
-0.02
1.127822
1.397671
otlertuzumab
kappa
ZU
scFv-Fc
Phase 2
false
2,013
null
EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS
EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK
kappa
WHO-INN
PL110
null
null
149.600654
68.5
600
10.959
10.267
0.07229
0
2.260983
9.516
-0.03
1.171753
1.781697
ozanezumab
kappa
ZU
IgG1
Phase 2
false
2,012
null
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK
kappa
WHO-INN
PL108
null
null
97.074688
67
0
10.034
8.632
0.05569
0.771314
27.692332
9.046
0.45
2.029358
4.452579
palivizumab
kappa
ZU
IgG1
Approved
false
1,998
null
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK
kappa
US Patent
US7704505
null
null
243.119698
79.5
900
9.332
8.705
0.03666
0
-0.852685
8.491
-0.03
1.118847
2.876539
panitumumab
kappa
HU
IgG2
Approved
false
2,004
null
QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK
kappa
US Patent
US8628773
null
null
179.587857
78.5
900
9.479
8.799
0.03631
0
-1.084605
8.42
-0.03
1.062088
1.182696
panobacumab
kappa
HU
IgM
Phase 2
false
2,008
null
EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS
DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK
kappa
WHO-INN
PL100
null
null
107.597686
69
900
9.827
8.85
0.02071
0
-0.415577
8.992
-0.01
1.212667
1.896839
parsatuzumab
kappa
ZU
IgG1
Phase 2
true
2,012
null
EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK
kappa
WHO-INN
PL107
null
null
40.019327
64.5
900
9.109
8.781
0.08654
0.134444
7.400359
8.651
0.12
10.046527
17.395674
patritumab
kappa
HU
IgG1
Phase 3
false
2,011
null
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS
DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK
kappa
WHO-INN
PL106
null
null
68.77442
71.5
600
10.15
9.321
0.05371
0.520073
13.086408
9.445
0.04
2.346217
4.34609